Q1 2022

Filed May 12, 2022 · 10-Q · 42 days after period end · 0001615219-22-000079

Q1 2022 · 10-Q

Revenue

$0.00

−100.0% vs Q1 2021

Net Income

-$6.11M

N/M vs Q1 2021

EPS Diluted

-$3.30

N/M vs Q1 2021

Operating Income-$6,117,229N/M

Operating Cash Flow

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	$0.00	$1.27M	$1.13M	$655.64K
Net Income	-$6.11M	-$1.85M	-$2.08M	-$1.52M
EPS Diluted	-$3.30	-$0.06	-$0.22	-$0.64

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR